Table 3.
Association between laboratory Parameters and Outcome (Death) in total study population.
| All Parameters Mean ± std.dev |
Outcome (full Sample) |
p value | |
|---|---|---|---|
| Survived (n = 46) | Died (n = 14) | ||
| Group∗∗∗ | <0.0011 | ||
| S | 6 (13.0%) | 14 (100.0%) | |
| A | 20 (43.5%) | 0 (0.0%) | |
| H | 20 (43.5%) | 0 (0.0%) | |
| Age (Years)∗∗∗ | 37.91 ± 13.46 | 62.08 ± 17.12 | <0.0012 |
| Gender∗∗∗ | 0.0141 | ||
| Male | 41 (89.1%) | 8 (57.1%) | |
| Female | 5 (10.9%) | 6 (42.9%) | |
| Socio-Economic Status | 0.2811 | ||
| Good | 13 (28.3%) | 1 (7.1%) | |
| Medium | 26 (56.5%) | 11 (78.6%) | |
| Poor | 7 (15.2%) | 2 (14.3%) | |
| D-Dimer (ng/ml) | 2020.76 ± 2086.76 | 2685.36 ± 1769.03 | 0.0732 |
| S. Ferritin∗∗∗ | 223.00 ± 240.32 | 425.52 ± 353.87 | 0.0482 |
| TAG | 191.37 ± 111.64 | 205.07 ± 83.33 | 0.3972 |
| Haemoglobin (g/dL)∗∗∗ | 13.33 ± 2.27 | 11.70 ± 1.66 | 0.0032 |
| Haematocrit (%) | 38.20 ± 8.03 | 36.40 ± 4.80 | 0.0872 |
| TLC (/cu.mm)∗∗∗ | 7546.30 ± 2574.58 | 17073.57 ± 7079.49 | <0.0012 |
| ANC (/cu.mm)∗∗∗ | 5244.46 ± 2527.45 | 14806.50 ± 6319.92 | <0.0012 |
| Lymphocytes (/cu.mm)∗∗∗ | 2180.46 ± 697.14 | 1989.43 ± 1785.99 | 0.0292 |
| Monocytes (/cu.mm)∗∗∗ | 121.39 ± 124.68 | 277.64 ± 205.59 | 0.0032 |
| Platelet Count (Lac/cu.mm) | 1.98 ± 1.23 | 1.75 ± 0.88 | 0.5122 |
| Quantiferon TB Gold∗∗∗ | 2.78 ± 4.42 | 0.02 ± 0.02 | <0.0012 |
| Quantiferon TB Gold +ve (>0.35 iu/ml) (Positive)∗∗∗ | 23 (50.0%) | 0 (0.0%) | <0.0013 |
| Mitogen∗∗∗ | 10.52 ± 5.93 | 0.37 ± 0.43 | <0.0012 |
| TO Antigen | 1.0001 | ||
| <50 | 38 (82.6%) | 12 (85.7%) | |
| 50–100 | 8 (17.4%) | 2 (14.3%) | |
| TH Antigen | 0.3551 | ||
| <50 | 30 (65.2%) | 11 (78.6%) | |
| 50–100 | 12 (26.1%) | 1 (7.1%) | |
| >100 | 4 (8.7%) | 2 (14.3%) | |
| AH Antigen∗∗∗ | 0.0381 | ||
| <50 | 44 (97.8%) | 11 (78.6%) | |
| 50–100 | 1 (2.2%) | 3 (21.4%) | |
| Influenza Vaccine (Present) | 0 (0.0%) | 0 (0.0%) | 1.0003 |
| BCG Scar (Present) | 36 (78.3%) | 12 (85.7%) | 0.7131 |
| Diabetes (Present) | 5 (10.9%) | 1 (7.1%) | 1.0001 |
| ACE Inhibitor Use (Present) | 5 (10.9%) | 2 (14.3%) | 0.6601 |
| Steroid, HCQS, Convalescent plasma Use (Present) | 0 (0.0%) | 0 (0.0%) | 1.0003 |
| Religious Practices (Present) | 42 (91.3%) | 14 (100.0%) | 0.5641 |
∗∗∗Significant at p < 0.05, 1: Fisher's Exact Test, 2: Wilcoxon-Mann-Whitney U Test, 3: Chi-Squared Test.